June 23, 2022
Effective for dates of service on or after May 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series.
Providers may use administration code 0074A (immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease (COVID-19)] vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose) for the booster dose.
More information can be found on the Pfizer-BioNTech COVID-19 Vaccine webpage. Updated provider manual sections will be released in a future Medi-Cal Update.